Navigation Links
NVA237 Phase III GLOW2 Data at American Thoracic Society (ATS) International Conference and Phase II Clinical Trial Update
Date:5/16/2012

inical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 


'/>"/>
SOURCE Sosei Group Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. NVA237 Filed in Europe and Positive Phase III Data at European Respiratory Society Congress
2. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
3. Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237
4. NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium
5. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
6. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
7. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
8. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
9. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
10. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... MENLO PARK, Calif. , June ... (OTCQX: DMPI) ("DelMar" and the "Company"), a ... cancer therapies in new orphan drug indications, today ... clinical trial of  VAL-083  (dianhydrogalactitol) in patients with ... deadly form of human brain cancer. ...
(Date:6/1/2015)... SAN DIEGO , June 1, 2015  Diomics, ... Richard M. Weissman , global financial executive, has ... Mr. Weissman has more than 25 years of industry ... Diomics, he served as a managing director at Credit ... UBS and Morgan Stanley/Dean Witter. "Diomics is ...
(Date:6/1/2015)... 1, 2015  AbbVie (NYSE: ABBV ) will ... June 4, 2015. Richard A. Gonzalez , chairman ... and answer session at 8:30 a.m. Central time. ... be accessible through AbbVie,s Investor Relations Web site at ... will be available later that day. ...
Breaking Medicine Technology:DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 2DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 4DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 5DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 6DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 7DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 8Richard M. Weissman joins Diomics Board of Directors 2
... SuccessEHS, a nationally recognized, streamlined practice management and ... ambulatory care software solution with a signature Success Architecture ... With this pairing, SuccessEHS is well-positioned to meet ... The essential technical, functional and reporting needs of a ...
... 21, 2011 Sheffield Bio-Science, a Kerry Group Business, ... alliance with Wockhardt Ltd. Under this partnership, Sheffield Bio-Science ... for recombinant insulin manufactured by global Indian biotech Wockhardt. ... is around US$ 50 million. Speaking on ...
Cached Medicine Technology:SuccessEHS Announces its Enterprise Ambulatory EHR Solution for Hospitals 2SuccessEHS Announces its Enterprise Ambulatory EHR Solution for Hospitals 3SuccessEHS Announces its Enterprise Ambulatory EHR Solution for Hospitals 4Sheffield Bio-Science and Wockhardt Announce Worldwide Exclusive Partnership to Supply Recombinant Insulin to Cell Culture Market 2
(Date:6/1/2015)... Sharenote, a leading web-base electronic healthcare software ... this week in Louisiana. The entrepreneurial trio behind Sharenote, ... provide potential providers with the tools and resources to ... within their network. , Find out why Sharenote ... by more than 250 practices. , Four Day ...
(Date:6/1/2015)... June 01, 2015 KC and Monica ... $88,000 of the best superfood products in ... floods in Texas. , "Monica and I are ... News in distributing Living Fuel Super Meals - SuperBerry®, ... millennial floods in Texas," KC Craichy said. "We have ...
(Date:6/1/2015)... 2015 More than 22 million children may ... school is out and they lose access to free or ... dairy farmers and milk companies are on a mission to ... Great American Milk Drive. , In many cases, food ... school cafeteria for the bulk of their daily nutrition. Although ...
(Date:6/1/2015)... CA (PRWEB) June 01, 2015 ... Assili are now offering patients a promotion on Invisalign ... price of Invisalign treatment is reduced to $3,700. Patients ... during the complimentary consultation and discuss the extent of ... and it cannot be combined with any other offer. ...
(Date:6/1/2015)... Listen to Volvo’s Director of Connectivity ... using more granular data to create better customer oriented ... voices in Josep Celaya Gonzalez, CIO at MAPFRE, and ... an automotive insurer, MAPFRE are well versed in capturing ... to the driver. Award winning start-up ParkTAG offer an ...
Breaking Medicine News(10 mins):Health News:Nearly $100,000 In Emergency Food Aid to Flood Victims in Texas Provided by Living Fuel and Natural News 2Health News:Nearly $100,000 In Emergency Food Aid to Flood Victims in Texas Provided by Living Fuel and Natural News 3Health News:Summer Nutrition Vital for Kids who Depend on Schools for Healthy Foods 2Health News:Northridge Dentists, Drs. Michel Elyson and Ramin Assili, are Now Offering a Limited Time Promotion on Invisalign 2Health News:Complimentary Webinar: Volvo, MAPFRE and Award Winning Start-Up discuss new Frontier of In-Car Services 2
... consumption, study finds , , THURSDAY, Nov. 27 (HealthDay News) ... other sugar-sweetened drinks from school cafeteria menus will have ... , Because these drinks are believed to be ... in the United States, many schools across the nation ...
... Montreal, Canada, November 27, 2008 Suffering from ... at the Centre hospitalier de l,Universit de Montral (CHUM), ... high efficacy hemodiafiltration (HDF). , An extracorporeal blood ... the HDF unit was introduced in CHUM,s Nephrology section, ...
... inhibits bacterial growth, experts say , , THURSDAY, Nov. ... cranberry sauce on your plate this Thanksgiving, because it may ... the American Urological Association. , The high acid content ... remedy for simple UTIs, help inhibit bacterial growth along the ...
... 27 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc.,(NYSE: ... medical device,research and development outsourcing company with operations ... Hu, the Company,s Chief Operating,Officer, will present at ... December 3, 2008, at 12:00 pm Eastern Standard ...
... auction special Pinot Noirs to benefit healthcare services for seasonal vineyard ... for 17 years, producers preview outstanding 2007 vintage. , ... ... Salud! The Oregon Pinot Noir Auction contributed generously to the 17th ...
... patients will benefit, researchers say , , WEDNESDAY, Nov. 26 (HealthDay ... with a certain type of non-Hodgkin lymphoma have a better ... , Three different signatures of gene activity, or ... gene -- have been identified in people with diffuse large ...
Cached Medicine News:Health News:School Soda Ban Has Limited Effect 2Health News:Major North American breakthrough for dialysis patients 2Health News:Major North American breakthrough for dialysis patients 3Health News:Cranberries May Help Prevent Urinary Tract Infections 2Health News:WuXi PharmaTech to Present at 20th Annual Piper Jaffray Healthcare Conference 2Health News:Despite Economy, Oregon Wine Benefit !Salud! Raises Over $735,000 2Health News:Despite Economy, Oregon Wine Benefit !Salud! Raises Over $735,000 3Health News:Genes May Predict Lymphoma Treatment Outcome 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: